Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTEC
Previous Symbol
CUSIPN/A
Phone972-2586-4657
Debt
Debt-to-Equity RatioN/A
Current Ratio9.22
Quick Ratio9.22
Price-To-Earnings
Trailing P/E Ratio-4.55
Forward P/E Ratio-5.64
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.26 per share
Price / Book3.32
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-29,090,000.00
Net MarginsN/A
Return on Equity-66.73%
Return on Assets-60.24%
Miscellaneous
Employees70
Outstanding Shares32,830,000
Market Cap$241.27 million
OptionableOptionable
Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma (NASDAQ:NTEC) issued its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03. View Intec Pharma's Earnings History.
When is Intec Pharma's next earnings date?
What price target have analysts set for NTEC?
5 brokers have issued 12 month price objectives for Intec Pharma's shares. Their forecasts range from $8.50 to $16.00. On average, they anticipate Intec Pharma's share price to reach $12.8750 in the next year. This suggests a possible upside of 71.7% from the stock's current price. View Analyst Price Targets for Intec Pharma.
What is the consensus analysts' recommendation for Intec Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intec Pharma.
Has Intec Pharma been receiving favorable news coverage?
News headlines about NTEC stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intec Pharma earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), Principia Biopharma (PRNB) and Radius Health (RDUS).
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 51)
- Mr. Nir Sassi, Chief Financial Officer (Age 42)
- Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 49)
- Mr. Walt Addison Linscott, Chief Admin. Officer (Age 57)
- Anne Marie Fields, VP of Corp. Communications & Investor Relations
When did Intec Pharma IPO?
(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.
Who are Intec Pharma's major shareholders?
Intec Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Prosight Management LP (4.07%), Harel Insurance Investments & Financial Services Ltd. (2.01%), Migdal Insurance & Financial Holdings Ltd. (1.80%), ARK Investment Management LLC (0.33%), Laurion Capital Management LP (0.29%) and PNC Financial Services Group Inc. (0.23%).
Which major investors are selling Intec Pharma stock?
NTEC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
Which major investors are buying Intec Pharma stock?
NTEC stock was bought by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Prosight Management LP, ARK Investment Management LLC, Laurion Capital Management LP, Migdal Insurance & Financial Holdings Ltd. and PNC Financial Services Group Inc..
How do I buy shares of Intec Pharma?
Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
One share of NTEC stock can currently be purchased for approximately $7.50.
How big of a company is Intec Pharma?
Intec Pharma has a market capitalization of $241.27 million. The biotechnology company earns $-29,090,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.
What is Intec Pharma's official website?
How can I contact Intec Pharma?
Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]
MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
